Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
Summary
Eli Lilly has increased its annual sales projections for the third time this year, driven by surging demand for its popular weight-loss medication. As the pharmaceutical company maintains its strong position in the American prescription weight-loss sector, its shares are experiencing a market rally.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.